HJLI Logo

Hancock Jaffe Laboratories Inc (HJLI) Stock Forecast & Price Prediction

Live HJLI Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NASDAQ | |

$3.05

-0.01 (-0.26%)

12 Month Price Forecast For HJLI

$3.05
Current Price
$29.58M
Market Cap
0 Ratings
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings

Distance to HJLI Price Forecasts

N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A

HJLI Price Momentum

-4.1%
1 Week Change
-5.9%
1 Month Change
-40.4%
1 Year Change
-0.7%
Year-to-Date Change
-56.2%
From 52W High of $6.97
+24.5%
From 52W Low of $2.45

๐Ÿค” Considering Hancock Jaffe (HJLI)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 11, 2025 3:31 AM UTC

HJLI Analyst Ratings & Price Targets

Currently, there are no Wall Street analyst price targets or forecasts available for HJLI (Hancock Jaffe).

HJLI is currently trading at $3.05. Without active analyst coverage, investors should conduct thorough independent research and consider multiple data points beyond price targets when evaluating this stock for their portfolio.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

HJLI Analyst Consensus

0
Buy
0
Hold
0
Sell

HJLI Price Target Range

Low
N/A
Average
N/A
High
N/A
Current: $3.05

Latest HJLI Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for HJLI.

Date Firm Analyst Rating Change Price Target

Stocks Similar to Hancock Jaffe Laboratories Inc

The following stocks are similar to Hancock Jaffe based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Hancock Jaffe Laboratories Inc (HJLI) Financial Data

Hancock Jaffe Laboratories Inc has a market capitalization of $29.58M with a P/E ratio of -0.4x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.

Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +14.9%.

Valuation Metrics

Market Cap $29.58M
Enterprise Value $21.13M
P/E Ratio -0.4x
PEG Ratio 0.0x
Price/Sales 0.0x

Growth & Margins

Revenue Growth (YoY) N/A
Gross Margin N/A
Operating Margin N/A
Net Margin N/A
EPS Growth N/A

Financial Health

Cash/Price Ratio +206.8%
Current Ratio 76.2x
Debt/Equity 0.0x
ROE +14.9%
ROA -103.5%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Hancock Jaffe Laboratories Inc logo

Hancock Jaffe Laboratories Inc (HJLI) Company Overview

About Hancock Jaffe Laboratories Inc

What They Do

Business Model

Additional Information

Company Information

Sector

Industry

Employees

0

CEO

Country

United States

IPO Year

2018

Hancock Jaffe Laboratories Inc (HJLI) Latest News & Analysis

HJLI stock latest news image
Quick Summary

Hancock Jaffe Laboratories CEO Robert Berman will participate in a webinar on September 27, 2021, at 1:00 PM ET, hosted by Ladenburg Thalmann.

Why It Matters

The webinar with Hancock Jaffe's CEO may provide insights into the company's strategy and performance, influencing investor sentiment and stock price.

Source: Accesswire
Market Sentiment: Neutral
HJLI stock latest news image
Quick Summary

Hancock Jaffe Laboratories Inc (NASDAQ: HJLI) will rebrand as enVVeno Medical Corporation (ticker: NVNO) on October 1, focusing exclusively on its VenoValve for treating venous disease.

Why It Matters

The rebranding and strategic focus on the VenoValve signal a commitment to a core product, potentially enhancing investor confidence and future growth prospects for enVVeno Medical.

Source: Benzinga
Market Sentiment: Positive
HJLI stock latest news image
Quick Summary

Hancock Jaffe is rebranding as enVVeno Medical Corporation (NASDAQ: NVNO) effective October 1, 2021, focusing on venous disease and unveiling a new product in mid-2022.

Why It Matters

Rebranding to enVVeno Medical and focusing on venous disease could signal a strategic shift, potentially enhancing growth prospects and attracting investor interest in innovative medical solutions.

Source: Accesswire
Market Sentiment: Neutral
HJLI stock latest news image
Quick Summary

Hancock Jaffe Laboratories, Inc. will hold a corporate update conference call and live video webcast on September 21, 2021, at 4:30 p.m. ET.

Why It Matters

The upcoming conference call may reveal key updates on Hancock Jaffe's product development and financial performance, impacting investor sentiment and stock price.

Source: Accesswire
Market Sentiment: Neutral
HJLI stock latest news image
Quick Summary

Hancock Jaffe Laboratories (NASDAQ: HJLI) has secured a $20 million investment from Perceptive Advisors through a registered direct offering of 2,540,650 shares at $7.8720 each.

Why It Matters

Hancock Jaffe's $20 million equity offering enhances its financial stability, enabling further development of its medical devices, which could drive future growth and investor returns.

Source: Accesswire
Market Sentiment: Neutral
HJLI stock latest news image
Quick Summary

Hancock Jaffe Laboratories, focused on bioprosthetics for cardiovascular diseases, received IDE approval in April 2021 for a pivotal trial of its VenoValve in the U.S.

Why It Matters

Hancock Jaffe's IDE approval for the VenoValve trial indicates potential advancements in cardiovascular treatment, which could drive revenue growth and increase stock value.

Source: Seeking Alpha
Market Sentiment: Positive

Frequently Asked Questions About HJLI Stock

What is Hancock Jaffe Laboratories Inc's (HJLI) stock forecast for 2025?

Analyst forecasts for Hancock Jaffe Laboratories Inc (HJLI) are not currently available. The stock is trading at $3.05.

Is HJLI stock a good investment in 2025?

Analyst ratings for HJLI are not currently available. The stock is currently trading at $3.05. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for HJLI stock?

Price predictions from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.05.

What is Hancock Jaffe Laboratories Inc's business model?

N/A

What is the highest forecasted price for HJLI Hancock Jaffe Laboratories Inc?

Price targets from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.05.

What is the lowest forecasted price for HJLI Hancock Jaffe Laboratories Inc?

Price targets from Wall Street analysts for HJLI are not currently available. The stock is trading at $3.05.

What is the overall HJLI consensus from analysts for Hancock Jaffe Laboratories Inc?

Analyst ratings for HJLI are not currently available. The stock is trading at $3.05.

How accurate are HJLI stock price projections?

Stock price projections, including those for Hancock Jaffe Laboratories Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.